Novo Nordisk A/S Becomes Insulin Market Leader
PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Novo Nordisk , a world leader in diabetes care, has announced that for the first time the company has moved into a leadership position in the U.S. insulin market based on the most recent data on total insulin volume.(i)
(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO )
This growth trend is centered around Novo Nordisk's flagship insulin products: NovoLog(R) Mix 70/30 (70% insulin aspart protamine suspension and 30 percent insulin aspart injection, [rDNA origin]), and NovoLog(R) (insulin aspart [rDNA origin] injection). Additionally, NovoLog Mix 70/30 FlexPen(R) and NovoLog FlexPen(R) are the leading insulin delivery devices in the U.S.
Martin Soeters, president of Novo Nordisk said, "The upward growth trend in Novo Nordisk's share of the insulin market underscores the fact that physicians are recognizing the value that our products can offer people who have diabetes. Additionally, we anticipate further growth with the launch of Levemir(R) (insulin detemir [rDNA origin] injection) in 2006. Treating patients with our full portfolio of insulin analogs is how we directly improve patient care on a daily basis."
About Diabetes
Diabetes, a disease in which the body does not produce or properly use insulin, affects more than 20 million people in the U.S., or 7 percent of the population, of which 6.2 million people are unaware that they have the condition. Diabetes is the sixth leading cause of death by disease in the U.S. and costs an estimated $132 billion per year in medical expenses and lost productivity. According to the World Health Organization, the total number of people with diabetes worldwide is projected to rise from 171 million in 2000 to 366 million in 2030.
About NovoLog Mix 70/30
NovoLog Mix 70/30 is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia. Because NovoLog Mix 70/30 has peak pharmacodynamic activity one hour after injection, it should be administered with meals. NovoLog Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog Mix 70/30 or one of its excipients. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog Mix 70/30.
About NovoLog
NovoLog is a rapid acting form of insulin for the treatment of patients with diabetes mellitus (type 1 and type 2) for the control of hyperglycemia. It enters the bloodstream quickly and begins working within minutes to lower blood glucose. The rapid onset and short duration of action mimic the insulin action of a person without diabetes. NovoLog offers convenient mealtime dosing and should be dosed immediately or up to 10 minutes before a meal. NovoLog is available in the prefilled NovoLog FlexPen insulin delivery system and is approved for use in insulin pumps. NovoLog is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin aspart or
one of its excipients. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog.
About Levemir
Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long acting) insulin for the control of hyperglycemia. Levemir is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin detemir or its excipients. Hypoglycemia is the most common adverse effect of insulin therapy, including Levemir. Levemir should not be diluted or mixed with any other insulin preparations.
Any change in insulin should be made cautiously and only under medical supervision.
Full prescribing information is available by contacting Novo Nordisk Inc. or visiting http://www.novonordisk-us.com.
About Novo Nordisk
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In the United States, Novo Nordisk's ambition is Changing Diabetes. Working as a catalyst to improve diabetes prevention and treatment, the company strives to be the preferred partner for employees, patients, healthcare providers, and others in the healthcare system who share its vision to defeat diabetes. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs approximately 21,600 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol "NVO." For global information, visit http://www.novonordisk.com; for United States information, visit http://www.novonordisk-us.com.
NovoLog, FlexPen, and Levemir are registered trademarks of Novo Nordisk A/S.
(i) SOURCE: IMS, National Sales Perspective, September 2005
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGOPRN Photo Desk photodesk@prnewswire.comNovo NordiskCONTACT: Media: Susan Jackson, +1-609-919-7776, or Rose Talarico,+1-609-919-7944, or Investors: Mads Veggerby Lausten, +1-609-919-7937, allof Novo Nordisk